Clinical experiences and case review of angiotensin II receptor blocker-related angioedema in Korea

Basic & Clinical Pharmacology & Toxicology
Hyunah KimHun Sung Kim

Abstract

Although angiotensin-converting enzyme inhibitor-related angioedema is well known, angiotensin II receptor blocker (ARB)-related angioedema has not been extensively studied because of its lower incidence. Therefore, ARB-related angioedema is likely to be overlooked in the clinical setting. We analysed the medical records of adults who had been prescribed ARB and diagnosed with angioedema between 2009 and 2015. All adults over the age of 18 years who were initially administered ARB between 1 January 2009 and 31 December 2015 were selected as participants in this study. To confirm whether the angioedema was actually due to the administration of ARB, we conducted a chart review. A total of 35 584 patients were prescribed ARB for the first time when visiting the Seoul St. Mary's Hospital during the study period. Twenty-four patients diagnosed with angioedema for other reasons prior to their first prescription of ARB were excluded from this study. ARB-related angioedema was suspected in six of 35 560 patients (0.02%) who were initially prescribed ARB during the study period. The manifestation of ARB-related angioedema ranged from several days (1/6 case) to several years (3/6 cases). Some patients continued taking ARB with intermitte...Continue Reading

References

Nov 1, 1992·The American Journal of Emergency Medicine·C J FinleyA E Nunez
Aug 19, 1988·JAMA : the Journal of the American Medical Association·E E SlaterP W Ewan
Jul 16, 1997·JAMA : the Journal of the American Medical Association·N J BrownM R Griffin
Oct 20, 1998·Archives of Internal Medicine·E W van RijnsoeverJ Feenstra
Dec 22, 1999·Immunopharmacology·A AgostoniJ Nussberger
Sep 1, 2000·Lancet·F H Messerli, J Nussberger
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Laurence G Howes, Diane Tran
May 3, 2002·Journal of Human Hypertension·R Hernández-HernándezR Cammarata
Aug 23, 2005·Journal of the American Academy of Dermatology·Allen P Kaplan, Malcolm W Greaves
Nov 2, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Catherine DemersRobert S McKelvie
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Aug 30, 2008·The New England Journal of Medicine·Salim YusufUNKNOWN PRoFESS Study Group
Dec 6, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Bret R HaymoreKent J DeZee
Feb 1, 2010·Indian Journal of Medical Sciences·Chitra Nair
Apr 24, 2012·The American Journal of Cardiology·Harikrishna MakaniSripal Bangalore
Nov 28, 2012·Allergology International : Official Journal of the Japanese Society of Allergology·Naoko Inomata
Nov 26, 2013·Journal of the American College of Cardiology·Miklos Z MolnarCsaba P Kovesdy
Apr 6, 2017·The Journal of Allergy and Clinical Immunology. in Practice·Aleena BanerjiLi Zhou

❮ Previous
Next ❯

Citations

Jan 29, 2019·Journal of Korean Medical Science·Hun-Sung Kim, Ju Han Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.